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Abstract
Shape memory polymer (SMP) foams are a class of smart materials
that show promise for managing uncontrolled hemorrhage on the
battlefield. The current standard treatments of gauze and tourniquets are
not able to effectively control hemorrhage in up to 80% of combat injuries.
Most hemostatic devices also require removal within 12 hours of
application. Patient transportation to a facility for removal may not be
possible within this time frame and the removal process itself can cause
further damage to the wound. As an alternative hemostatic device,
polyurethane SMP foams have shown to be effective and biocompatible
hemostats; however, removal still remains a concern. Degradable SMP
foams have been developed through modification of a previously tested
polyurethane SMP system to overcome this limitation. In this work, in vitro
hemocompatibility and overall blood interactions with these degradable
SMP foams is assessed. The primary outcome of these studies shows that
the polyurethane SMP foams maintain hemocompatibility with incorporation
of specific degradable components. The data collected here will aid in
further development of this degradable SMP system as well assist future in
vitro and in vivo studies leading into clinical trials of this SMP system for
hemostatic applications.
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1. Introduction
1.1 Clinical Need: Uncontrolled Hemorrhage
Every year, approximately 1.5 million lives are lost due to uncontrolled
hemorrhage. Of the casualties that occur on the battlefield, hemorrhage from traumatic
injury accounts for half of combat fatalities as well as 80% of combat deaths that are
potentially survivable [1]. The majority of these deaths occur before military personnel
can be moved to a medical facility for treatment. Injured personnel can bleed out over
the course of hours, though most deaths occur in the first 5-10 minutes after injury [2],
[3]. Being able to quickly control bleeding in the combat zone is a critical part of
reducing the number of soldiers KIA (killed in action before reaching a medical facility).
As the body loses large quantities of blood, there is no longer adequate oxygen
delivery to critical organs in the body and a person undergoes hemorrhagic shock.
Damage to kidneys, liver, intestines are among the initial effects of severe blood loss.
As hemorrhage continues and there is inadequate oxygen delivery to the brain and
myocardium, brain damage and fatal arrhythmias follow [4]. Being able to slow and
control this bleeding before a person reaches a medical care facility will not only
improve patient survival but decrease lasting damage in survivors [1].

1.2 Current Solutions: Advantages and Disadvantages
While there are multiple hemostatic devices and dressings in clinical use, a
significant need remains for an effective hemostat that is easy to apply, does not require
time sensitive/complicated removal, and is biocompatible.
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Tourniquets are among the current standards of care on the battlefield for controlling
hemorrhage. Tourniquets are commonly used in combat as they are relatively quick and
easy way to slow bleeding. However, use of a tourniquet for longer than 4 hours can
cause permanent nerve and tissue damage [5]. Additionally, confusion among military
personnel on safe practices with application, loosening, and removal of the tourniquet
can lead to improper use and unnecessary nerve paralysis and limb ischemia [6].
Despite the prevalence of tourniquets as a standard of care on the battlefield, they are
only effective in 7% of cases [5]. Use of gauze for packing a wound is another
commonly used treatment for hemorrhage control. In general, packing a wound with
gauze controls hemorrhage by creating pressure within the wound cavity that is
sufficient to stop bleeding from vessels [7]. QuikClot (QCCG) is a promising gauze
dressing in clinical use that employs the clay material kaolin to activate the coagulation
cascade and speed up clotting time as compared to traditional gauze [8], [9]. Overall,
gauze is relatively inexpensive and easy to apply, however periodic dressing changes
are needed which can be time consuming and the removal process can cause re-bleeds
and further damage to the wound [5].

XStat is a hemostat currently in use that has shown to be effective at quickly
slowing bleeding with the advantage of easier application than gauze and tourniquet.
XStat comes in the form of a syringe applicator with 92 small sponges that are injected
into a wound cavity. Upon entering the wound these sponges expand to fill the space,
absorbing blood and applying pressure to the wound walls. Though effective, the
sponges have the disadvantage of increasing removal time 22-fold compared to
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traditional gauze [10]. The need to remove XStat sponges within 4 hours of application
introduces a further complication, as transportation to a medical facility where this can
be performed may not be possible in this amount of time.

1.3 Shape Memory Polymer Foams
Shape memory polymers (SMPs) are ‘smart’ materials that can be reversibly
deformed and fixed into a temporary secondary shape, and later recovered to the
original primary shape in the presence of a specific stimulus [11]. Thermal SMPs in
particular are fabricated to have a permanent or primary shape and can be heated
above the material’s transition temperature, deformed, and cooled to fix in the
secondary shape for storage or transportation (illustrated in Figure 1). Upon application
of a thermal stimulus that is above the SMP’s transition temperature, the material will
return to its primary fixed shape [12].

Figure 1. Illustration of SMP shape programming and recovery.

Our group has developed a temperature sensitive polyurethane SMP foam
system for use as a hemostat. This SMP has a dry transition temperature above body
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temperature (Tg > 40°C) and can remain in its secondary shape for storage and
transportation in both very cold and hot environments. When wet, (e.g. after insertion
into a bleeding wound) the transition temperature of this SMP is reduced to below body
temperature (Tg < 37°C) due to disruption of hydrogen bonds and overall plasticization,
and shape change occurs [13]. Polyurethane SMP foams to date have demonstrated
great biocompatibility, rapid clotting ability due to high surface area and thrombogenic
surface chemistry, high tunability of actuation temperature as well as unique shape
retention properties [14]–[16].This SMP system shows promise for hemostatic
applications, as it can be transported at a small volume, actuated upon exposure to
body temperature blood in a bleed site, and expanded to promote hemostasis through
application of pressure and thrombogenic properties.

One of the important features of this SMP system is the ability to tune the
chemistry and adjust properties for specific applications. To address the limitations of
hemostats currently in use, degradable linkages have been incorporated into the
backbone of our polyurethane SMP system to create a degradable hemostatic device
[17]. Specifically, 15% or 30% nitrilotriacetic acid-diethylene glycol (NTA-DEG), 30%
triethylene glycol (TEG), or 30% diethylene glycol (DEG) monomers have been included
into the control polyurethane foam composition of hexamethylene diisocyanate (HDI),
triethanolamine (TEA), and N,N,N’,N’-tetrakis(2-hydroxypropyl) ethylenediamine
(HPED). A degradable hemostatic foam would not need to be removed and could be
left in place during the healing process (Figure 2), decreasing the urgency for patient
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transport to a medical facility and avoiding further damage and rebleeds due to wound
dressing removal.

Figure 2. Expansion of degradable shape memory polymer in a bleed.

The original SMP foam formulation has shown consistently rapid blood clotting in
pre-clinical models; however, blood interactions must be evaluated in new formulations
to ensure that these desirable clotting properties are maintained.

1.4 Hemocompatibility
Contained in the blood are various components, including red blood cells (RBCs)
that are responsible for oxygen transport (44%), plasma (55%), platelets that play a role
in recognizing foreign substances and initiate clotting, and leukocytes responsible for
immune response (~1%) [18]. Together these components play a crucial role in the
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human body. As such, hemocompatibility is one of the most important criteria for a
material that is to be used in vivo. International guidance has been developed for any
blood-contacting medical devices, requiring hemocompatibility evaluation according to
International Organization for Standardization (ISO) 10993-4, “Selection of Tests for
Interactions with Blood” [19], [20].

While the specific tests required by ISO differ based on the application of the
material or device, there is a list of main test categories recommended for evaluation,
including: thrombosis, coagulation, platelet function, hematology, and immunology.
Hemocompatibility is defined by the lack of adverse interactions or destruction of any
blood components. For the application of our polyurethane SMP, we sought to evaluate
our system’s ability to induce clotting by looking at the time for stable clot formation to
occur as well as the recruitment and activation of platelets. This material differs from
“traditional” hemocompatible materials as it is intended to function as a hemostat, and
thrombogenic (clot inducing) properties are desirable. Further, the hematology of the
material was assessed through hemolysis measurement.

1.4.1 Coagulation
Hemostasis following injury occurs by two main mechanisms in the body, platelet
plug formation (primary hemostasis) and the coagulation cascade (secondary
hemostasis). These two independent processes work together to result in a strong clot
at the damaged region of the vessel that is impermeable to blood and as a result, stops
bleeding [21]. This clot is primarily composed of activated platelets, fibrin, and red blood
cells that are entrapped within the network at the site of vessel damage. The
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coagulation cascade consists of two separate pathways that converge to ultimately lead
to the formation of the insoluble protein fibrin that assembles into a highly branched
network [22]. The intrinsic pathway of coagulation is initiated when the first factor in the
pathway, Factor XII or serine protease, is exposed to endothelial collagen due to trauma
within the vascular system. From here a cascade of activations of other factors leads to
the conversion of prothrombin into thrombin, which then cleaves fibrinogen into the fibrin
monomer that makes up the essential “mesh” network of a clot [23]. The extrinsic
pathway, also called the tissue factor (TF) pathway, is initiated by external trauma to the
vascular system that results in TF coming into contact with blood. A cascade similar to
the intrinsic pathway results in the formation of thrombin that again serves to convert
fibrinogen into fibrin. By having two different pathways of coagulation activation, the
initiation, growth and maintenance of fibrin can be better controlled and regulated
throughout the clot formation process [24].

1.4.2 Platelet Adhesion and Activation
Alternatively, circulating platelets play an important role in hemostasis by forming
a plug through activation and adhesion to the site of injury. Most studies for
hemocompatible materials focus on minimizing or avoiding platelet activation, though for
the application of a hemostat, platelet activation and adhesion are desirable [25]. When
a vessel is damaged and endothelial collagen is exposed, this collagen as well as von
Willebrand factor (vWF) will bind the platelets to the site of damage. This binding
process and the thrombin formed during the coagulation cascade lead to the activation
of platelets, and the platelets in turn release their cellular components (granules).
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Release of granule contents functions to further recruit, aggregate and adhere
circulating platelets to the damaged vessel [26], [27].

1.4.3 Hemolysis
Hemolysis, defined as the rupture of RBCs and the release of their contents, is a
crucial indicator of the fragility of the RBC membrane when in contact with a particular
material. Hemolysis can occur due to mechanical forces or as a result of material
mediated interactions, which is what we primarily focus on here. In general, hemolysis is
undesirable as it can impact the body’s ability to transport oxygen to tissues, and the
presence of free hemoglobin can cause inflammation and vascular dysfunction [28].

Overview
In this study I look at the interactions of degradable shape memory polymer
foams with porcine blood to provide a preliminary assessment of the hemocompatibility
of this material. This data will aid in future in vitro and in vivo studies leading into clinical
trials of this SMP system as a hemostatic device. The tests performed in this work are
adapted from other studies in literature to assess coagulation, hemolysis, and platelet
attachment and activation responses of our degradable SMP foams when in contact
with blood.
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2. Methods
2.1 Test Samples
Polyurethane foams were prepared in a 2-step reaction between isocyanates
(NCO) and hydroxyls (OH) as previously described by Singhal et al [16]. Foam
formulations included a control composed of hexamethylene diisocyanate (HDI),
triethanolamine (TEA), and N,N,N’,N’‐tetrakis(2‐hydroxypropyl) ethylenediamine
(HPED). Biostable foams included 30% diethylene glycol (DEG) or 30% triethylene
glycol (TEG) in place of TEA. Biodegradable foams included 15% or 30% nitrilotriacetic
acid-DEG (NTA)-DEG. Foam compositions are shown in Table 1. QuikClot Combat
Gauze (QCCG) and XStat were utilized as clinical controls.
Table 1. Foam formulations tested in blood interaction studies.
Sample

HDI
(mol%

TEA

HPED

DEG

(mol%

(mol%

(mol%

OH)

OH)

OH)

TEG
(mol%

NTA-DEG
(mol%

OH)

NCO)

OH)

Control

100%

30%

70%

--

--

--

30% DEG

100%

--

70%

30%

--

--

30% TEG

100%

--

70%

--

30%

--

15% NTA-DEG

100%

15%

70%

--

--

15%

30% NTA-DEG

100%

--

70%

--

--

30%

Foam density and pore size specific to each foam formulation (previously measured)
were used to calculate the mass required so that all foam samples had equal surface
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area in each study. The surface areas used to calculate sample size and the foam
masses for each study are shown in Table 2.
Table 2. Surface areas and foam masses for each blood interaction study.
Study
Surface
Control
30% DEG
30% TEG
15% NTAArea

30% NTADEG (mg)

(mg)

(mg)

(mg)

DEG (mg)

32.60

3.54

3.70

2.0

3.74

1.96

Hemolysis

143.8

78.0

81.4

44.1

82.6

43.1

LDH Assay

34.81

18.9

19.72

10.68

20.0

10.43

(cm2)
Coagulation
Time

2.2 Blood Absorption
For initial measurement of blood interactions with samples, blood absorption was
analyzed after incubation of SMPs and clinical controls (gauze and XStat®) in blood.
Porcine blood (Lampire Biological Laboratories, Pipersville, PA, USA) anticoagulated
with Na-Citrate upon collection was stored at 4°C in a refrigerator for up to 3 weeks from
the bleed date until ready to be used. Approval for the use of porcine blood was
obtained from the Syracuse University Biosafety Committee prior to experimentation.
Dry samples (n=3, ~50 mg) were weighed and incubated in 2 mL of porcine blood at
37°C. Two sets of absorption measurements were collected, one from a 1-hour
incubation period and the other from a 24-hour incubation period. Samples were
weighed at the end of the incubation time, and blood absorption was calculated as:
% 𝐴𝑏𝑠𝑜𝑟𝑏𝑒𝑑 =

𝑊𝑏 − 𝑊𝑑
𝑥 100%
𝑊𝑑

Where Wb is the sample’s mass in blood and Wd is the dry mass.
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2.3 Coagulation Time Study
The relative time for complete clot formation was determined by incubating
samples with porcine blood followed by measuring lysate absorbance at six-minute
lysing intervals for 30 minutes. Samples (n=4) were analyzed at 0, 6, 12, 18 and 30
minutes. Previously weighed foam samples were placed in 1.5 mL centrifuge tubes
arranged in 4x5 formation prior to testing. Empty polypropylene tubes served as
negative (non-clotting) controls, and QCCG (gauze) and XStat were used as clinical
controls.

Porcine blood anticoagulated with Na-Citrate upon collection was stored at 4°C in
a refrigerator for up to 3 weeks from the bleed date until ready to be used. Ten mL of
blood was pipetted from the primary blood container into a separate tube and allowed to
rest at room temperature for 15 minutes. Then, 100 µL of 1 M CaCl2 was added to the
blood to obtain a final CaCl2 concentration of 0.01 M to reverse the anticoagulant. Using
a multichannel pipette, 50 µL of blood was immediately added to each centrifuge tube, a
stopwatch was started, and 1 mL of DI water was added to the 0 minute sample tubes
to stop the clotting progress and lyse free (not clotted) red blood cells. This lysing step
was repeated at each time point until the 30-minute time point was reached.

When all samples had been lysed, each tube was centrifuged at 2300 rpm for 15
minutes. Before imaging, 200 µL of lysate was taken from each tube and pipetted into a
96 well-plate. Then, tubes were inverted and imaged using a digital camera.
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Absorbance of the lysate was measured at 540 nm in a Biotek Synergy 2 Multi-Mode
Microplate Reader (Winooski, VT, USA) to determine the relative amount of hemoglobin
released at each time point, indicating the progress of clot formation at that time. Data
points for each 6-minute lyse point were averaged and plotted with respect to time.

2.4 Hemolysis Assay
To calculate percent hemolysis upon incubation with SMP foams, samples (n=6)
were weighed according to masses in Table 2 and placed in 15 mL centrifuge tubes.
Gauze and XStat were utilized as clinical controls. Prior to the experiment, all samples
were incubated in 1X phosphate buffered saline (PBS, Fisher Bioreagents, Fair Lawn,
NJ, USA) for 5 hours at 37°C. Positive (hemolytic) controls were empty polypropylene
tubes with 5 mL of DI water, and negative (non-hemolytic) controls were empty tubes
with 5 mL of PBS. Control tubes (n = 6) were incubated for 1 hour at 37°C. While foams
were incubating, a separate solution of 1X PBS was prepared and warmed to 37°C.
After incubation, samples were removed from the PBS and placed into a fresh, 15 mL
centrifuge tube containing 5 mL of the warmed 1X PBS.

Porcine blood was anticoagulated with Na-Citrate upon collection and was stored
at 4°C in a refrigerator until ready to be used. With all centrifuge tubes set up, 5 mL of
the blood was removed from the primary blood container, transferred to a separate test
tube and placed in a water bath at 37°C for 15 minutes. The tube of blood was then
gently inverted 5 times to mix. Then, 100 µL of whole blood was added to each sample
and control tube. All tubes were then incubated in a water bath at 37°C for 1 hour. To
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separate lysate from whole blood components, samples were centrifuged at 1000 rpm
for 10 minutes. Following centrifugation, 200 µL of supernatant was taken from each
tube and pipetted into a 96 well-plate. A Biotek Synergy 2 Multi-Mode Microplate
Reader (Winooski, VT, USA) was used to detect the absorbance of the released
hemoglobin for each well at 545 nm. Using collected absorbance (OD) values,
hemolysis was calculated as:
𝐻𝑒𝑚𝑜𝑙𝑦𝑠𝑖𝑠 (%) =

𝑂𝐷(𝑠𝑎𝑚𝑝𝑙𝑒) − 𝑂𝐷(𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
𝑥 100.
𝑂𝐷 (𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 ) − 𝑂𝐷(𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙)

2.4 Platelet Attachment (LDH Assay)
For quantifying the attachment of platelets to samples, a Cayman Chemical LDH
Cytotoxicity assay kit (Ann Arbor, MI, USA) was used after incubating SMP foams and
controls in whole blood, stored as described previously. Plasma was obtained through
centrifugation of whole blood at 3000 RPM for 15 minutes. A standard was generated
by diluting plasma with PBS to concentrations of: 100%, 50%, 25%, 12.5% and 6.25%.
Hemocytometer counts at each plasma concentration (n=4) were acquired and used for
standard values.
SMP foams (n = 4) were cut to have the same surface areas (Table 2) and
placed in the wells of a 24 well-plate. Then, 1 mL of whole was added to each sample
well, and the plate was incubated at 37°C for 30 minutes.

Non-attached platelets were washed away with PBS by first dipping samples in a
solution of 1X PBS then rinsing with a squirt bottle of PBS. Samples were transferred to
another plate containing 1 mL of fresh PBS in each well, and 100 µL 10% Triton X-100
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(Acros Organics, Fair Lawn, NJ, USA) was added to wells and incubated at 37°C for 1
hour to lyse the attached platelets. Then, 100 µL of supernatant was taken from each
sample well and transferred to a 96 well-plate. The LDH Reaction solution (100 µL,
included in kit) was added to each well, and the plate was incubated for 30 minutes at
37°C on an orbital shaker. Following incubation, absorbances were read on the
microplate reader at 490 nm.

In addition to LDH assay measurements, platelet attachment was quantified
through brightfield imaging with a Leica Inverted Fluorescent Microscope (Wetzlar,
Germany) Three random regions of interest on each sample were imaged at 40X
magnification and platelets counted manually.

2.5 Platelet Activation
SMP foams (approximately 0.5 cm3) were incubated in whole blood and rinsed of
non-attached platelets, according to the above procedure for the LDH assay. In order to
observe activity states and activation of the attached platelets, samples were prepared
for scanning electron microscope (SEM) imaging. Samples were fixed in a solution of
2% glutaraldehyde (Electron Microscopy Sciences, Hatfield, PA, USA) overnight at 4°C.
Following fixation, samples were dehydrated in solutions with increasing concentrations
of ethanol: 1) 30 minutes in 50% ethanol, 2) 30 minutes in 70% ethanol, 3) 30 minutes
in 95% ethanol, 4) 30 minutes in 100% ethanol. Final dehydration was accomplished
through drying overnight in a vacuum oven at room temperature, and samples were
sputter coated with 5-10 nm of gold.
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SEM analysis was performed using a Joel NeoScope JCM‐5000 Scanning
Electron Microscope (Peabody, MA, USA) at an operating voltage of 15 kV. Random
regions of interest were imaged at 5000X, 1000X and 500X. Images were analyzed
qualitatively for signs of platelet aggregation and morphology change.
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3. Results and Discussion
3.1 Blood Absorption
Degradation of the polyurethane foams primarily occurs through oxidation, where
the presence of reactive oxygen species breaks the bonds of tertiary amines present in
the monomers [29]. In the control foam, this oxidative degradation occurs relatively
slowly. The incorporation of either TEG or DEG slows down the foam degradation
process. The ester formulations with NTA-DEG degrade considerably faster than the
control foams due to the introduction of hydrolytically degradable ester bonds. Thus, this
selection of SMP foams (Control, 30% DEG, 30% TEG, 15% NTA-DEG, and 30% NTADEG) provide a spectrum of biodegradation rates. While the polyurethane SMP system
is hydrophobic overall, the inclusion of more hydrophilic DEG, TEG, or NTA-DEG to
tune degradation speed has the potential to affect interactions with blood. Generally,
proteins preferentially adsorb to hydrophobic surfaces [30]. Additionally, general
changes in the chemistry (e.g., introduction of new dipole-dipole bonds between ester
linkages in NTA-DEG foams) and charge (e.g., electronegative O in ether linkages in
DEG and TEG) can alter protein interactions with materials. In the clotting process, the
adsorption of fibrin as well as other blood proteins to a surface plays a crucial role in
thrombus formation [31]. Thus, it is important to characterize the effects of chemical
changes on blood interactions.

As an initial measure of blood interactions with these foams, blood adsorption
was measured at 1 and 24 hours.
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Figure 3. Blood absorbed over 1 hour and 24 hours at 37°C (n=3). Average ±
standard deviation displayed.

Blood absorption volumes (Figure 3) were found to be the highest in the control foam,
and lowest in 15% NTA-DEG. Dipole-dipole bonds in 15% NTA-DEG restrict water
access within chains and may be responsible for the comparatively low absorption
volume. When NTA-DEG content is increased to 30%, the hydrophilicity of DEG is
sufficient enough to surmount dipole-dipole interactions and allow for increased water
interactions within the network, and increased overall blood absorption. Blood
absorption for 15% NTA-DEG decreases slightly relative to the control foam after a 24hour incubation period, which could be due to a more open pore structure in 15% NTADEG that reduces the volume of blood that is retained after the sample is removed.
Looking at DEG and TEG foams absorption volumes, the open pore structure may have
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a similar effect on blood retention and explain why these foams absorbed less than the
control foam. DEG and TEG foams also introduce charges from dipoles that could
additionally impact interactions with proteins and overall blood absorption volume.

3.2 Coagulation Time

Figure 4. Blood clotting times as a function of absorbance at 540nm (n=3).
Average ± standard deviation displayed.

The coagulation time test used absorbance values of lysed blood as an indicator
of the clot formation progress. When DI water is added at each time point, free RBCs
(not in a stable clot) lyse and release hemoglobin into the supernatant solution. The
relative amount of hemoglobin released is determined through the absorbance reading,
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with higher absorbance values corresponding to a higher concentration of free
hemoglobin in the supernatant. As a stable blood clot forms, RBCs become trapped in
an impermeable network of platelets and fibrinogen and do not lyse upon the addition of
DI water [32]. Progress of clot formation is indicated by changes in the amount of
hemoglobin released at consecutive time points, with absorbance decreasing as a
stable clot forms and less RBCs are lysed when DI water is added. See Figure 5 for
representative images of lysates at each time point.

Figure 5. Representative images of lysates from coagulation time assay. Negative
control: empty tube.
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Results (Figure 4) showed that at 6 minutes, all of the SMP foams tested had
higher free hemoglobin concentrations than clinical controls (gauze and XStat),
suggesting less stable clots in the SMP foams. By 12 minutes, absorbance values for
SMPs and clinical controls reached comparable values, with slightly higher values
measured for 15% NTA-DEG. At 18 minutes, clot formation was stabilized, and all SMP
foam absorbances were within range of the clinical control values and lower than the
negative control. This result indicates that the incorporation of degradable linkages from
NTA-DEG slows down clot formation but does not adversely affect the overall clot
forming abilities of the SMP system. The inclusion of hydrophilic DEG and TEG does
not affect the overall hydrophobicity and/or charge of the polymer enough to impact the
interactions of platelets and blood proteins with the material surface, and ultimately
does not impact the material’s clotting abilities.

3.3 Hemolysis
Table 3. Percent Hemolysis measurements (n=3). Displayed as average ±
standard deviation.
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Percent hemolysis was determined following the incubation of samples with
blood via measurement of supernatant absorbance following centrifugation. Similar to
coagulation testing, the absorbance was an indicator of the concentration of free
hemoglobin present in the supernatant as a result of lysing. Under the testing conditions
performed here, any hemolysis that occurred can be assumed to be due to surfacematerial specific interactions rather than direct mechanical forces. When RBCs come
into contact with any synthetic material, the cell membrane is subject to stresses that
are dependent on the properties of the material such as: surface charge, the presence
of substrates, and surface curvature or topography, which may affect the extent of
interaction [33]. Results from this hemolysis assay (Table 3) indicate that all of the SMP
formulations induced approximately 0% hemolysis and were comparable to the negative
control (PBS) and the clinical control (gauze). Interestingly, the XStat clinical control
induced increased hemolysis, with high variability between samples.
This result demonstrates that the interfacial interactions between SMPs and blood cells
do not result in stresses large enough to disrupt the cell membrane and lead to cell
lysis. There is no established value of allowable hemolytic potential for blood contacting
materials, though any hemolysis is generally undesirable as it can lead to impaired
oxygen transport to tissues over time and other unwanted side effects. As these SMPs
caused approximately zero hemolysis upon incubation, we can conclude that the
hemolytic potential of these materials is minimal, which supports the overall
hemocompatibility of these SMP foams.
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3.4 Platelet Attachment
3.4.1 LDH Assay

Figure 6. Average concentration (platelets/mL) of attached platelets on
each sample (n=3). Average ± standard deviation displayed.

LDH is an enzyme that is found in the cytosol of most cell types of the body,
including platelets. This assay utilized the presence of LDH in platelets as a means of
quantifying how many platelets attached to each sample type. After lysing samples that
had been rinsed of non-attached platelets and adding an LDH reaction solution,
absorbance readings were fitted to a standard curve to determine the number of
attached platelets. In creating a standard curve (using hemocytometer counts plotted
against absorbance readings), decreasing concentrations of plasma resulted in a linear
decrease in platelet numbers that could be used to quantify the concentrations of
attached platelets on samples. Results can be found in Figure 6. The 30% DEG foams
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showed the highest levels of platelet attachment by far, with the next highest being
XStat®, having approximately half the number of attached platelets as compared to
DEG. The 30% TEG and control foams had comparable platelet attachment values to
the clinical controls, gauze and XStat®. Ester-containing foams, 15% NTA-DEG and
30% NTA-DEG, displayed slightly lower quantities of adhered platelets compared to
controls, which correlates with the blood absorption and coagulation time assay results.

Platelet attachment is a critical part of hemostasis and is essential in the
formation of a platelet plug at the site of vessel damage. As platelet attachment is
mediated by interactions between the platelet membrane and plasma proteins (such as
vWF) adsorbed onto a surface, results from this assay indicate the ability of plasma
proteins to adsorb to tested sample surfaces and induce platelet interactions.
As described previously, various surface characteristics, such as charge and relative
hydrophobicity, can impact protein adsorption to biomaterials. In the case of TEG and
DEG, results from this assay indicate that their incorporation into SMP foams did not
negatively impact the ability of platelets and plasma proteins to interact with the surface
of these materials. Specifically for 30% DEG, it appears that its presence greatly
improved surface interactions for platelets and proteins. This result requires further
investigation to better understand the mechanism.

Ester-containing (NTA-DEG) SMP formulations had lower platelet attachment
numbers, which is generally attributed to alterations in chemistry and secondary
interactions (i.e., between ester bonds), hydrophilicity, and foam morphology, all of
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which could affect how platelets interact with the surface. In general, platelets were
found attached to all samples, showing that platelet interactions and overall plug
formation are possible to varying degrees. This data interpreted in combination with
clotting time observations suggests that the while the relative number of platelets
attached to each sample and the relative rates of clotting differ, all foams are still
capable of inducing stable clot formation.

3.4.2 Brightfield Imaging

Figure 7. Representative brightfield images of attached platelets at 40X
magnification. Area for each image is approximately 0.110mm2.
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Table 4. Average platelet counts determined from brightfield images (n=3).
Average ± standard deviation displayed.

Brightfield imaging was performed in supplement to the LDH assay to give a
more detailed view of platelet interactions with each SMP formulation. Platelets were
manually counted and averaged to provide an additional reference for attachment
numbers (Table 4). Supporting results from the LDH assay, 30% DEG displayed a
much higher number of platelets on to the surface than all other samples, suggesting
favorable surface characteristics for platelet interactions. In this assay, the control SMP
foam performed relatively better and had higher platelet numbers than in the LDH
assay. The quantity of attached platelets on NTA-DEG and TEG foams were
comparable. Due to the fibrous nature of gauze, bright field images could not sufficiently
capture a large enough surface area of fibers in one focal plane to allow for platelet
quantification, and the image is omitted here. XStat® samples did not have enough
attached platelets to find and focus on. A representative image is included in Figure 7
(XStat); however, no platelet number is included because counting was not possible
with the obtained images.
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Figure 8. SEM images of samples before (control) and after (blood) incubation in
whole blood.
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3.5 Platelet Activation – SEM
SMP foams imaged by SEM gave a better idea of platelet activation and
aggregation behavior on each material. As seen in Figure 8, platelets were found on all
materials, in varying quantities and states. Generally, a circulating platelet that is not
activated is shaped like a biconcave disk as seen in Figure 7 (XStat). Activation can be
caused by multiple stimuli, including contact with von Willebrand factor that coincides
with attachment and exposure to thrombin produced through the coagulation cascade.
Once activation occurs and a platelet is adhered, the platelet will release granules from
its cytoplasm, which release various chemical mediators that play a role in coagulation
and inflammation [34]. This degranulation process can be seen in SEM images in
Figure 8 (blood samples) and is denoted by the small protrusions coming from the
platelets. All SMP samples imaged showed that platelets were activated and had
aggregated in clusters of varying sizes on the surfaces of the materials. Clinical controls
had a lower degree of platelet adhesion, with gauze appearing to have more platelet
activity and aggregation than on XStat®, which showed very few platelets and little to no
observable activation. As stable clot formation depends on the entrapment of RBCs and
activated platelets within a fibrin network, this SEM evidence of activation and
aggregation of platelets on SMP foams suggests that all tested foams support platelet
adhesion and activation.

When combined, these platelet studies indicate that the new foam formulations
with tunable degradation rates are able to support platelet adhesion and activation,
which is crucial to hemostasis and clot formation.
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4. Conclusions

The blood interaction tests performed in this work provide a preliminary
assessment of the hemocompatibility of degradable SMP foams. As polyurethane SMPs
have previously shown good biocompatibility and overall hemostatic performance, we
focused on determining how the inclusion of DEG, TEG, and NTA-DEG to tune
degradation rates impacts the material interactions with blood. Understanding how
these degradable SMPs interact with whole blood and blood components is a crucial
aspect of assessing the potential of these materials to be used clinically as hemostatic
devices in the future.
Degradable SMP foams demonstrated capability of stable clot formation, platelet
attachment, and overall hemocompatibility comparable to clinical controls. From the
data gathered here, it is evident that the chemical modifications do not affect the overall
clotting abilities of the SMPs, as all degradable foams were found to support protein
interactions and the formation of stable clots in vitro. However, inclusion of the estercontaining NTA-DEG does not appear to reduce platelet interactions and clotting
speeds. Future work to further investigate specific effects of surface charge and relative
hydrophobicity would be useful in understanding the mechanism of protein and platelet
interactions observed in this work.
Overall, the data obtained in this study provides important insight to the
performance of these materials as hemostatic devices. The methods established here
can be used for future studies to evaluate the performance of blood contacting materials
for hemostatic applications. Information gathered for each degradable SMP formulation
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will be useful in optimization of these materials and for future in vitro and in vivo preclinical trials.
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